Researchers from the University of Birmingham, in collaboration with liquid biopsy cancer detection and screening firm Nonacus, have announced GALEAS Bladder, a new non-invasive test for the detection of bladder cancer.
The device, a urine-based molecular test, was developed by Nonacus alongside a panel of biomarkers developed by Dr Douglas Ward and Professor Rik Bryan from the University of Birmingham’s Bladder Cancer Research Centre.
The test, which was unveiled at the Annual Meeting of the European Association of Urology, aims to detect bladder cancer quickly and accurately, meaning that diagnosis can be streamlined and reducing the need for patients to receive invasive cystoscopies.
GALEAS Bladder could potentially work across the entire pathway for bladder cancer treatment, reducing the reliance of the process on cystoscopies and imaging for bladder cancer surveillance and triage for haematuria.
The test detects bladder cancer in DNA from tumour cells which are present in urine. Analyses have confirmed that the test demonstrates high diagnostic accuracy, with sensitivity of >90 per cent and specificity of >85 per cent, for bladder cancer across all stages and grades.
Professor Rik Bryan from the University of Birmingham commented: "Since 2009, Doug Ward and I have been working on various strategies to accurately and reliably detect bladder cancer from a urine sample.”
“The DNA-based genomic approaches that we have been developing over the last eight years, with funding from Cancer Research UK and support and expertise from Nonacus, have allowed us to do just that with a test that appears to rival cystoscopy with regard to sensitivity and specificity for the diagnosis of bladder cancer in patients being investigated for haematuria.”
“Our unpublished data also demonstrates that it is possible to use the same mutation panel and Nonacus platform to identify circulating tumour DNA, thus raising the exciting possibility that a single approach can be used throughout the patient pathway.”
Nonacus CEO Chris Sale added: “We are very excited to launch GALEAS Bladder. We are striving to develop a suite of meaningful non-invasive tools that can have real impact on the diagnosis and treatment of patients with suspected cancer. GALEAS Bladder represents the first in this pipeline, helping to improve patients' lives and reducing the burden of cystoscopy on over stretched clinics.”
